BioCentury
ARTICLE | Clinical News

Fujifilm's T-817MA misses in Phase II for AD

July 21, 2017 12:28 AM UTC

Fujifilm Holdings Corp. (Tokyo:4901) reported data from a Phase II trial in about 484 patients with mild to moderate Alzheimer's disease showing that once-daily T-817MA missed the co-primary endpoints of improving AD Assessment Scale-Cognitive subscale (ADAS-Cog) and AD Assessment Scale-Clinical Global Impression of Change (ADAS-CGI-C) scores from baseline to week 52 vs. placebo.

The company also said there were no significant differences between treatment groups on secondary endpoints. Secondary endpoints in the double-blind, U.S. trial include safety, AD Cooperative Study-Activities of Daily Living (ADCS-ADL), Neuropsychiatric Inventory (NPI) and Mini-Mental State Examination (MMSE). Patients received placebo, once-daily 224 mg T-817MA, or once-daily 224 mg T-817MA for the first 4 weeks followed by once-daily 448 mg T-817MA...